The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse

Neurobiology of Disease

Volumn 68, Issue , 2014, Pages 1-15

  Savolainen, Mari H ^a,b   Richie, Christopher T ^b   Harvey, Brandon K ^b   Männistö, Pekka T ^a   Maguire Zeiss, Kathleen A ^c   Myöhänen, Timo T ^a,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autophagy; Dementia with lewy bodies; Parkinson's disease; Protein misfolding; Serine protease; Synucleinopathies; Synucleins

Indexed keywords

4 PHENYLBUTANOYL LEVO PROLYL 2 CYANOPYRROLIDINE; ALPHA SYNUCLEIN; BECLIN 1; BIOLOGICAL MARKER; DOPAMINE; ENZYME INHIBITOR; KYP 2047; MICROTUBULE ASSOCIATED PROTEIN; MICROTUBULE ASSOCIATED PROTEIN LIGHT CHAIN 3B I II; PROLYL ENDOPEPTIDASE; PROTEIN P62; UNCLASSIFIED DRUG; 4-PHENYLBUTANOYL-PROLYLCYANOPYRROLIDINE; ALANINE; PROLINE; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SNCA PROTEIN, MOUSE;

ANIMAL TISSUE; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL CULTURE; CELL FUNCTION; CONTROLLED STUDY; DOPAMINE BLOOD LEVEL; DRUG MECHANISM; ENZYME INHIBITION; GENETIC CODE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; TRANSGENIC MOUSE; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; BRAIN DISEASES; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MOTOR ACTIVITY; MUTATION; PATHOLOGY; TIME; TRANSFORMED CELL LINE;

ALANINE; ALPHA-SYNUCLEIN; ANIMALS; AUTOPHAGY; BRAIN; BRAIN DISEASES; CELL LINE, TRANSFORMED; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; MUTATION; PROLINE; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; TIME FACTORS;

EID: 84899869409     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.04.003     Document Type: Article

References (83)

1. Airavaara M., Mijatovic J., Vihavainen T., Piepponen T.P., Saarma M., Ahtee L. In heterozygous GDNF knockout mice the response of striatal dopaminergic system to acute morphine is altered. Synapse 2006, 59:321-329.
2. Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., Lee V.M., Trojanowski J.Q., Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 1998, 152:879-884.
3. Bellucci A., Navarria L., Falarti E., Zaltieri M., Bono F., Collo G., Grazia M., Missale C., Spano P. Redistribution of DAT/alpha-synuclein complexes visualized by "in situ" proximity ligation assay in transgenic mice modelling early Parkinson's disease. PLoS One 2011, 6:e27959.
4. Beraud D., Twomey M., Bloom B., Mittereder A., Ton V., Neitzke K., Chasovskikh S., Mhyre T.R., Maguire-Zeiss K.A. Alpha-synuclein alters Toll-like receptor expression. Front. Neurosci. 2011, 5:80.
5. Blommaart E.F., Krause U., Schellens J.P., Vreeling-Sindelarova H., Meijer A.J. The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur. J. Biochem. 1997, 243:240-246.
6. Brandt I., Gerard M., Sergeant K., Devreese B., Baekelandt V., Augustyns K., Scharpe S., Engelborghs Y., Lambeir A.M. Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein. Peptides 2008, 29:1472-1478.
7. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M., Waucquier N., Defebvre L., Amouyel P., Farrer M., Destee A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
8. Chen L., Thiruchelvam M.J., Madura K., Richfield E.K. Proteasome dysfunction in aged human alpha-synuclein transgenic mice. Neurobiol. Dis. 2006, 23:120-126.
9. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 1998, 4:1318-1320.
10. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:571-576.
11. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295.
12. Di Daniel E., Glover C.P., Grot E., Chan M.K., Sanderson T.H., White J.H., Ellis C.L., Gallagher K.T., Uney J., Thomas J., Maycox P.R., Mudge A.W. Prolyl oligopeptidase binds to GAP-43 and functions without its peptidase activity. Mol. Cell. Neurosci. 2009, 41:373-382.
13. Ebrahimi-Fakhari D., Cantuti-Castelvetri I., Fan Z., Rockenstein E., Masliah E., Hyman B.T., Mclean P.J., Unni V.K. Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein. J. Neurosci. 2011, 31:14508-14520.
14. Ebrahimi-Fakhari D., Wahlster L., Mclean P.J. Protein degradation pathways in Parkinson's disease: curse or blessing. Acta Neuropathol. 2012, 124:153-172.
15. Fellner L., Irschick R., Schanda K., Reindl M., Klimaschewski L., Poewe W., Wenning G.K., Stefanova N. Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia 2013, 61:349-360.
16. Feng L.R., Federoff H.J., Vicini S., Maguire-Zeiss K.A. Alpha-synuclein mediates alterations in membrane conductance: a potential role for alpha-synuclein oligomers in cell vulnerability. Eur. J. Neurosci. 2010, 32:10-17.
17. Fleming S.M., Chesselet M.F. Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism. Behav. Pharmacol. 2006, 17:383-391.
18. Fu L.L., Cheng Y., Liu B. Beclin-1: autophagic regulator and therapeutic target in cancer. Int. J. Biochem. Cell Biol. 2013, 45:921-924.
19. Fulop V., Bocskei Z., Polgar L. Prolyl oligopeptidase: an unusual beta-propeller domain regulates proteolysis. Cell 1998, 94:161-170.
20. Harwood A.J. Prolyl oligopeptidase, inositol phosphate signalling and lithium sensitivity. CNS Neurol. Disord. Drug Targets 2011, 10:333-339.
21. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H.A., Kittel A., Saitoh T. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995, 14:467-475.
22. Jakes R., Spillantini M.G., Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 1994, 345:27-32.
23. Jalkanen A.J., Puttonen K.A., Venäläinen J.I., Sinerva V., Mannila A., Ruotsalainen S., Jarho E.M., Wallen E.A., Männistö P.T. Beneficial effect of prolyl oligopeptidase inhibition on spatial memory in young but not in old scopolamine-treated rats. Basic Clin. Pharmacol. Toxicol. 2007, 100:132-138.
24. Jalkanen A.J., Hakkarainen J.J., Lehtonen M., Venäläinen T., Kaariainen T.M., Jarho E., Suhonen M., Forsberg M.M. Brain pharmacokinetics of two prolyl oligopeptidase inhibitors, JTP-4819 and KYP-2047, in the rat. Basic Clin. Pharmacol. Toxicol. 2011, 109:443-451.
25. Jalkanen A.J., Piepponen T.P., Hakkarainen J.J., De Meester I., Lambeir A.M., Forsberg M.M. The effect of prolyl oligopeptidase inhibition on extracellular acetylcholine and dopamine levels in the rat striatum. Neurochem. Int. 2012, 60:301-309.
26. Jarho E.M., Venäläinen J.I., Huuskonen J., Christiaans J.A., Garcia-Horsman J.A., Forsberg M.M., Järvinen T., Gynther J., Männistö P.T., Wallen E.A. A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors. J. Med. Chem. 2004, 47:5605-5607.
27. Jenco J.M., Rawlingson A., Daniels B., Morris A.J. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry 1998, 37:4901-4909.
28. Kadowaki M., Karim M.R. Cytosolic LC3 ratio as a quantitative index of macroautophagy. Methods Enzymol. 2009, 452:199-213.
29. Kahle P.J., Neumann M., Ozmen L., Haass C. Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein. Ann. N. Y. Acad. Sci. 2000, 920:33-41.
30. Kang R., Zeh H.J., Lotze M.T., Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011, 18:571-580.
31. Kato A., Fukunari A., Sakai Y., Nakajima T. Prevention of amyloid-like deposition by a selective prolyl endopeptidase inhibitor, Y-29794, in senescence-accelerated mouse. J. Pharmacol. Exp. Ther. 1997, 283:328-335.
32. Komatsu M., Ichimura Y. Physiological significance of selective degradation of p62 by autophagy. FEBS Lett. 2010, 584:1374-1378.
33. Kraft C., Martens S. Mechanisms and regulation of autophagosome formation. Curr. Opin. Cell Biol. 2012, 24:496-501.
34. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
35. Lambeir A.M. Interaction of prolyl oligopeptidase with alpha-synuclein. CNS Neurol. Disord. Drug Targets 2011, 10:349-354.
36. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., Dawson T.M., Copeland N.G., Jenkins N.A., Price D.L. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53→Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:8968-8973.
37. Lee H.J., Cho E.D., Lee K.W., Kim J.H., Cho S.G., Lee S.J. Autophagic failure promotes the exocytosis and intercellular transfer of alpha-synuclein. Exp. Mol. Med. 2013, 45:e22.
38. Lindholm P., Voutilainen M.H., Lauren J., Peranen J., Leppanen V.M., Andressoo J.O., Lindahl M., Janhunen S., Kalkkinen N., Timmusk T., Tuominen R.K., Saarma M. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 2007, 448:73-77.
39. Männistö P.T., Venäläinen J., Jalkanen A., Garcia-Horsman J.A. Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders. Drug News Perspect. 2007, 20:293-305.
40. Mantle D., Falkous G., Ishiura S., Blanchard P.J., Perry E.K. Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease. Clin. Chim. Acta 1996, 249:129-139.
41. Marighetto A., Touzani K., Etchamendy N., Torrea C.C., De Nanteuil G., Guez D., Jaffard R., Morain P. Further evidence for a dissociation between different forms of mnemonic expressions in a mouse model of age-related cognitive decline: effects of tacrine and S 17092, a novel prolyl endopeptidase inhibitor. Learn. Mem. 2000, 7:159-169.
42. Martinez-Vicente M., Cuervo A.M. Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol. 2007, 6:352-361.
43. Mijatovic J., Airavaara M., Planken A., Auvinen P., Raasmaja A., Piepponen T.P., Costantini F., Ahtee L., Saarma M. Constitutive Ret activity in knock-in multiple endocrine neoplasia type B mice induces profound elevation of brain dopamine concentration via enhanced synthesis and increases the number of TH-positive cells in the substantia nigra. J. Neurosci. 2007, 27:4799-4809.
44. Miracco C., Cosci E., Oliveri G., Luzi P., Pacenti L., Monciatti I., Mannucci S., De Nisi M.C., Toscano M., Malagnino V., Falzarano S.M., Pirtoli L., Tosi P. Protein and mRNA expression of autophagy gene Beclin 1 in human brain tumours. Int. J. Oncol. 2007, 30:429-436.
45. Miyazaki A., Toide K., Sasaki Y., Ichitani Y., Iwasaki T. Effect of a prolyl endopeptidase inhibitor, JTP-4819, on radial maze performance in hippocampal-lesioned rats. Pharmacol. Biochem. Behav. 1998, 59:361-368.
46. Morain P., Lestage P., De Nanteuil G., Jochemsen R., Robin J.L., Guez D., Boyer P.A. S 17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment. Preclinical and clinical studies. CNS Drug Rev. 2002, 8:31-52.
47. Murphy D.D., Rueter S.M., Trojanowski J.Q., Lee V.M. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 2000, 20:3214-3220.
48. Myöhänen T.T., Venäläinen J.I., Tupala E., Garcia-Horsman J.A., Miettinen R., Männistö P.T. Distribution of immunoreactive prolyl oligopeptidase in human and rat brain. Neurochem. Res. 2007, 32:1365-1374.
49. Myöhänen T.T., Venäläinen J.I., Garcia-Horsman J.A., Piltonen M., Männistö P.T. Cellular and subcellular distribution of rat brain prolyl oligopeptidase and its association with specific neuronal neurotransmitters. J. Comp. Neurol. 2008, 507:1694-1708.
50. Myöhänen T.T., Venäläinen J.I., Garcia-Horsman J.A., Piltonen M., Männistö P.T. Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues. Histochem. Cell Biol. 2008, 130:993-1003.
51. Myöhänen T.T., Hannula M.J., Van Elzen R., Gerard M., Van Der Veken P., Garcia-Horsman J.A., Baekelandt V., Männistö P.T., Lambeir A.M. A prolyl oligopeptidase inhibitor, KYP-2047, reduces alpha-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease. Br. J. Pharmacol. 2012, 166:1097-1113.
52. Pan T., Kondo S., Le W., Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 2008, 131:1969-1978.
53. Peltonen I., Jalkanen A.J., Sinerva V., Puttonen K.A., Männistö P.T. Different effects of scopolamine and inhibition of prolyl oligopeptidase on mnemonic and motility functions of young and 8- to 9-month-old rats in the radial-arm maze. Basic Clin. Pharmacol. Toxicol. 2010, 106:280-287.
54. Peltonen I., Myöhänen T.T., Männistö P.T. Different interactions of prolyl oligopeptidase and neurotensin in dopaminergic function of the rat nigrostriatal and mesolimbic pathways. Neurochem. Res. 2012, 37:2033-2041.
55. Penttinen A., Tenorio-Laranga J., Siikanen A., Morawski M., Rossner S., Garcia-Horsman J.A. Prolyl oligopeptidase: a rising star on the stage of neuroinflammation research. CNS Neurol. Disord. Drug Targets 2011, 10:340-348.
56. Petiot A., Ogier-Denis E., Blommaart E.F., Meijer A.J., Codogno P. Distinct classes of phosphatidylinositol 3'-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. J. Biol. Chem. 2000, 275:992-998.
57. Petroi D., Popova B., Taheri-Talesh N., Irniger S., Shahpasandzadeh H., Zweckstetter M., Outeiro T.F., Braus G.H. Aggregate clearance of alpha-synuclein in Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on the proteasome. J. Biol. Chem. 2012, 287:27567-27579.
58. Piltonen M., Savolainen M., Patrikainen S., Baekelandt V., Myöhänen T.T., Männistö P.T. Comparison of motor performance, brain biochemistry and histology of two A30P alpha-synuclein transgenic mouse strains. Neuroscience 2013, 231:157-168.
59. Plaas M., Karis A., Innos J., Rebane E., Baekelandt V., Vaarmann A., Luuk H., Vasar E., Koks S. Alpha-synuclein A30P point-mutation generates age-dependent nigrostriatal deficiency in mice. J. Physiol. Pharmacol. 2008, 59:205-216.
60. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
61. Przedborski S., Chen Q., Vila M., Giasson B.I., Djaldatti R., Vukosavic S., Souza J.M., Jackson-Lewis V., Lee V.M., Ischiropoulos H. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J. Neurochem. 2001, 76:637-640.
62. Rockenstein E., Mallory M., Hashimoto M., Song D., Shults C.W., Lang I., Masliah E. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res. 2002, 68:568-578.
63. Rubinsztein D.C., Codogno P., Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat. Rev. Drug Discov. 2012, 11:709-730.
64. Seglen P.O., Gordon P.B. 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:1889-1892.
65. Shinoda M., Miyazaki A., Toide K. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and on cholinergic and peptidergic neurons in rats with ibotenate-induced lesions of the nucleus basalis magnocellularis. Behav. Brain Res. 1999, 99:17-25.
66. Sidhu A., Wersinger C., Vernier P. Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?. FASEB J. 2004, 18:637-647.
67. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
68. Spillantini M.G., Goedert M. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann. N. Y. Acad. Sci. 2000, 920:16-27.
69. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6469-6473.
70. Surguchov A. Molecular and cellular biology of synucleins. Int. Rev. Cell. Mol. Biol. 2008, 270:225-317.
71. Szeltner Z., Morawski M., Juhasz T., Szamosi I., Liliom K., Csizmok V., Tolgyesi F., Polgar L. GAP43 shows partial co-localisation but no strong physical interaction with prolyl oligopeptidase. Biochim. Biophys. Acta 2010, 1804:2162-2176.
72. Toide K., Shinoda M., Fujiwara T., Iwamoto Y. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and central cholinergic neurons in aged rats. Pharmacol. Biochem. Behav. 1997, 56:427-434.
73. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., Otero D.A., Kondo J., Ihara Y., Saitoh T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:11282-11286.
74. Unger E.L., Eve D.J., Perez X.A., Reichenbach D.K., Xu Y., Lee M.K., Andrews A.M. Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice. Neurobiol. Dis. 2006, 21:431-443.
75. Uversky V.N. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J. Neurochem. 2007, 103:17-37.
76. Uversky V.N., Li J., Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 2001, 276:44284-44296.
77. Van der Veken P., Fulop V., Rea D., Gerard M., Van Elzen R., Joossens J., Cheng J.D., Baekelandt V., De Meester I., Lambeir A.M., Augustyns K. P2-substituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: biochemical evaluation, binding mode determination, and assessment in a cellular model of synucleinopathy. J. Med. Chem. 2012, 55:9856-9867.
78. Venäläinen J.I., Garcia-Horsman J.A., Forsberg M.M., Jalkanen A., Wallen E.A., Jarho E.M., Christiaans J.A., Gynther J., Männistö P.T. Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors. Biochem. Pharmacol. 2006, 71:683-692.
79. Watanabe Y., Tatebe H., Taguchi K., Endo Y., Tokuda T., Mizuno T., Nakagawa M., Tanaka M. p62/SQSTM1-dependent autophagy of Lewy body-like alpha-synuclein inclusions. PLoS One 2012, 7:e52868.
80. Wersinger C., Sidhu A. Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci. Lett. 2003, 340:189-192.
81. Yamamoto A., Tagawa Y., Yoshimori T., Moriyama Y., Masaki R., Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct. Funct. 1998, 23:33-42.
82. Yoshimoto T., Kado K., Matsubara F., Koriyama N., Kaneto H., Tsura D. Specific inhibitors for prolyl endopeptidase and their anti-amnesic effect. J. Pharmacodyn. 1987, 10:730-735.
83. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Gomez Tortosa E., del Ser T., Munoz D.G., de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.